Trials / Unknown
UnknownNCT03629873
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
A Phase 2 Study Evaluating Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, multi-center, open study to evaluating efficacy and safety of Chi-BEAC combining with auto-HSCT to treat aggressive lymphoma Subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide | Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m\^2 IVD d-6; Etoposide 150mg/m\^2/d qd IVD d-5\~-2; Cytarabine 150mg/m\^2 q12h IVD d-5\~-2; Cyclophosphamide 1.0g/m\^2/d qd IVD d-5\~-2 |
Timeline
- Start date
- 2018-02-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2018-08-14
- Last updated
- 2022-01-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03629873. Inclusion in this directory is not an endorsement.